Imaging features of hepatic arterial and venous flow abnormalities
AASLD LiverLearning®, Vincent Mellnick, 206009
Clinical studies investigating the effect of vitamin E therapy in patients with NASH
AASLD LiverLearning®, Sebastian Larion, 206010
Review of hepatobiliary contrast agents: Current applications and challenges
AASLD LiverLearning®, Alex Frydrychowicz, 206011
Fontan‐associated liver disease: Monitoring progression of liver fibrosis
AASLD LiverLearning®, Tamir Diamond, 206012
Intra‐arterial locoregional therapy in the management of hepatocellular carcinoma
AASLD LiverLearning®, Anil Seetharam, 206013
Risk factors for progression of and treatment options for NAFLD in children
AASLD LiverLearning®, Phillipp Hartmann, 206014
Use of proton pump inhibitors in chronic liver diseases
AASLD LiverLearning®, Raymond Chung, 206003
Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis
AASLD LiverLearning®, Kellie Young MD, 206004
Management of nosocomial spontaneous bacterial peritonitis: A complex and moving target
AASLD LiverLearning®, Amy G. Ogurick, 206005
Medication nonadherence in liver transplantation
AASLD LiverLearning®, Maureen Whitsett, 206006
A2 liver transplantation across the ABO barrier: Increasing options in the donor pool?
AASLD LiverLearning®, Jin Ge, 206007
Congestive hepatopathy: Differentiating congestion from fibrosis
AASLD LiverLearning®, Alexander Lemmer, 206008
The gut microbiome and nonalcoholic fatty liver disease
AASLD LiverLearning®, Brian Nadeau, 203819
Primary sclerosing cholangitis: Unique aspects of disease in children
AASLD LiverLearning®, Jillian M. Cotter, 203820
ABO‐incompatible liver transplantation: Is it a viable option with modern innovation?
AASLD LiverLearning®, Abbas Rana, 203821
Pathological patterns of biliary disease
AASLD LiverLearning®, Jason Lewis, 203822
Nonobese nonalcoholic fatty liver disease
AASLD LiverLearning®, sammy saab, 203823
Drug‐drug interactions in hepatitis C virus treatment: Do they really matter?
AASLD LiverLearning®, Paul Kwo, 203824
Controversies in hepatitis C therapy: Reactivation of hepatitis B virus
AASLD LiverLearning®, Michael Fried, 203451
HCV treatment in patients with decompensated liver disease
AASLD LiverLearning®, Elizabeth C. Verna, 203452
Substance use disorders before and after liver transplantation
AASLD LiverLearning®, Jason L. Eccleston, 203453
Nonsurgical options for localized hepatocellular carcinoma
AASLD LiverLearning®, Johnathan Ha, 203454
Normothermic machine perfusion of the liver
AASLD LiverLearning®, CORRESPONDENCE Garrett R. Roll, 203455
Small‐for‐size syndrome in LT
AASLD LiverLearning®, Taizo Hibi, 203456
Clinical  Hepatology Debrief
AASLD LiverLearning®, Kris Kowdley, 202145
Clinical  Hepatology Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202146
NAFLD Debrief
AASLD LiverLearning®, Kymberly Watt, 202143
NAFLD Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202144
Hepatitis Debrief
AASLD LiverLearning®, Paul Kwo, 202141
Hepatitis Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202142
Leon Schiff SOA: Acute on Chronic Liver Failure
AASLD LiverLearning®, Patrick Kamath, 202139
Leon Schiff SOA: Acute on Chronic Liver Failure: Introduction
AASLD LiverLearning®, Guadalupe Garcia-Tsao, 202140
Mayo Spheroid Reservoir Bio-Artificial Liver Improves Survival and Promotes Liver Regeneration in Post Hepatectomy ALF Pigs
AASLD LiverLearning®, Harvey Chen, 201444
Chemical and Toxicology Analysis of Ayurvedic and Herbal Drugs Causing Severe Liver Injury
AASLD LiverLearning®, Cyriac Philips, 201445
Evaluation of spheroid reservoir bioartificial liver with porcine hepatocytes in rhesus monkey model of acute liver failure
AASLD LiverLearning®, YI LI, 201446
Development of a new inhibitory antibody for prevention of HCV infection
AASLD LiverLearning®, Ken Okai, 201447
Human stem cell-derived Encapsulated Mature Liver Tissue as an effective, consistent, and durable in vitro tool for drug testing and development
AASLD LiverLearning®, Massimiliano Paganelli, 201448
The Frequency of Herbal and Dietary Supplement Mislabeling: Experience of the Drug Induced Liver Injury Network
AASLD LiverLearning®, Victor Navarro, 201449
Postgraduate Course 2017
AASLD LiverLearning®, Session Speakers, 206302
HCV Patient Populations With Challenging Treatment Decisions
AASLD LiverLearning®, Paul Pockros, 202138
Ultrasound-based Elastography for NAFLD
AASLD LiverLearning®, Laurent Castera, 202132
New HCV Therapies in 2017 and Their Impact on Treatment Strategies
AASLD LiverLearning®, Paul Kwo, 202137
Global Perspectives on HCV Eradication
AASLD LiverLearning®, Philippa Easterbrook, 202136
Magnetic Resonance Elastography for NAFLD
AASLD LiverLearning®, Rohit Loomba, 202131
From the AASLD-IDSA Guidance Committee: How We Make Our Recommendations, What Important Gaps Remain in the Care of HCV Patients?
AASLD LiverLearning®, Susanna Naggie, 202135
HCV 2017 Treatment Symposium: Program Chair
AASLD LiverLearning®, Andrew Muir, 202133
Assessing Severity of Portal Hypertension and Prognosis
AASLD LiverLearning®, Massimo Pinzani, 202130
How Accurate is the Diagnosis of Cirrhosis?
AASLD LiverLearning®, Sumeet Asrani, 202129
AASLD/EASL Symposium: Non-invasive Assessment of Liver Disease: Program Chair
AASLD LiverLearning®, Jayant Talwalkar, 202127
Global Forum: The Global Burden of Non-alcoholic Fatty Liver Disease: Closing Remarks
AASLD LiverLearning®, Zobair Younossi, 202124
NAFLD in Children: A Global Perspective
AASLD LiverLearning®, Miriam Vos, 202123
African Content Perspective – AFASLD
AASLD LiverLearning®, Hisham El Khayat, 202122
South American Perspective – ALEH
AASLD LiverLearning®, Marco Arrese, 202121
Asia-Pacific Perspective – APASL
AASLD LiverLearning®, Barjesh Sharma, 202120
Hans Popper Basic Science SOA: Gut Microbiota and Liver
AASLD LiverLearning®, Bernd Schnabl, 202125
European Perspective – EASL
AASLD LiverLearning®, Frank Tacke, 202119
Hans Popper Basic Science SOA: Gut Microbiota and Liver: Introduction
AASLD LiverLearning®, Gavin Arteel, 202126
Global Forum: The Global Burden of Non-alcoholic Fatty Liver Disease: Program Chair
AASLD LiverLearning®, Zobair Younossi, 202116
Should Patients with HCV Early Stage & HCC Receive Concomitant Therapy?
AASLD LiverLearning®, Laura Kulik, 202110
New Treatment Algorithm for Management of Autoimmune Hepatitis
AASLD LiverLearning®, John Vierling, 202115
Do DAA Therapies for HCV Increase HCC Recurrence: No?
AASLD LiverLearning®, Amit Singal, 202109
New Strategies for Diagnosis and Surveillance of Cholangiocarcinoma in PSC
AASLD LiverLearning®, Christoph Schramm, 202114
Do DAA Therapies for HCV increase HCC Recurrence: Yes?
AASLD LiverLearning®, Maria Reig, 202108
Advances in the Management of PBC
AASLD LiverLearning®, Christopher Bowlus, 202113
Do DAA Therapies for HCV Increase HCC Recurrence Following Liver Transplantation: Yes?
AASLD LiverLearning®, Michael Leise, 202105
HCV SVR and HCC Incidence: DAA Era
AASLD LiverLearning®, Nathalie GANNE CARRIE, 202104
Hepatobiliary Neoplasia SIG: HCV Therapy and HCC: Program Chair
AASLD LiverLearning®, Gregory Gores, 202100
Hepatobiliary Neoplasia SIG: HCV Therapy and HCC: Session I Moderator
AASLD LiverLearning®, Augusto Villanueva, 202102
HCV SVR and HCC Incidence: Interferon Era
AASLD LiverLearning®, Hashem B. El-Serag, 202103
Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science
AASLD LiverLearning®, Mark Avigan, 202098
Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science: Introduction
AASLD LiverLearning®, Robert Fontana, 202099
ClinIcal Educator/Mentor Award (DCEMA)
AASLD LiverLearning®, Session Speakers, 202097
Metagenomic analysis shows a shift in taxonomic and functional composition of the gut microbiota in NASH patients
AASLD LiverLearning®, Jerome Boursier, 195709
A National Survey of Physicians Regarding Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH): The Disease and Clinical Trial Awareness Program for NASH
AASLD LiverLearning®, Zobair Younossi, 195775
Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
AASLD LiverLearning®, Stephen Harrison, 195660
The Impact Of Obeticholic Acid (OCA) On Atherogenic Lipoproteins In Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Arun Sanyal, 195688
Disruption of hepatic IL-1 signaling improves insulin sensitivity and hepatic inflammation in a model of non-alcoholic fatty liver disease (NAFLD).
AASLD LiverLearning®, Nadine Gehrke, 195524
Lipoprotein sub-fractions show increased cardiovascular disease risk in pediatric non-alcoholic steatohepatitis compared to non-alcoholic fatty liver
AASLD LiverLearning®, Juna Konomi, 195634
Evaluating the Response to Placebo in Randomized Controlled Trials of Nonalcoholic Steatohepatitis: A systematic review and meta-analysis
AASLD LiverLearning®, Ma Ai Thanda Han, 195675
NGM282 Ameliorates Hepatic Lipotoxicity as Measured by Lipidomics and Gene Expression in a Diet-Induced Mouse Model of Nonalcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Lei Ling, 195548
Cross talk between Sirtuins and TGF-β signaling - new models for non alcoholic steatohepatitis and progression to HCC
AASLD LiverLearning®, Lopa Mishra, 195531
Beneficial effects of combined farnesoid X receptor agonist (INT747) and dipeptidyl peptidase-4 inhibitor (sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
AASLD LiverLearning®, Naotaka Shimozato, 195540
The secretin (SCT)/secretin receptor (SR) axis alters microRNA levels carried in extracellular vesicles that are responsible for cell-cell communication between cholangiocytes
AASLD LiverLearning®, Keisaku Sato, 195286
Role of endothelial dysfunction in microRNA-34a knockout mice with cholestatic liver injury
AASLD LiverLearning®, Tianhao Zhou, 195287
YAP/β-catenin cross-talk promotes a pro-inflammatory phenotype in Fibrocystin-defective cholangiocytes
AASLD LiverLearning®, Luca Fabris, 195288
An essential role of macrophages in cholangiocyte regeneration in a model of specific cholangiocyte injury
AASLD LiverLearning®, Adrien Guillot, 195289
Heritable variation of redox homeostasis is a potential risk factor for biliary disease
AASLD LiverLearning®, Xiao Zhao, 195290
Targeting YAP in Cholangiocarcinoma (CCA) induces cell senescence while blocking cell proliferation
AASLD LiverLearning®, Massimiliano Cadamuro, 195292
Cholangiocytes from Patients with Primary Biliary Cholangitis Display The Warburg Effect with Increased Mitochondria, Oxygen Consumption and Glycolytic Activity
AASLD LiverLearning®, Filip Wysokinski, 195293
Inhibition of HDAC6 and autophagy reverts ciliary loss and decreases proliferation rates in cholangiocarcinoma cells
AASLD LiverLearning®, Estanislao Peixoto, 195294
Changing Expression Profiles of lncRNAs, mRNAs, circRNAs and miRNAs in Biliary Epithelial Cells after Bile Acid (TDCA) Stimulation
AASLD LiverLearning®, Eric Gershwin, 195295
Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC).
AASLD LiverLearning®, Tianhao Zhou, 195296
The microRNA-200c Is a Critical Novel Regulator of Cholestatic Liver Fibrosis
AASLD LiverLearning®, Yongfeng Song, 195298
Pharmacological inhibition of ASBT-mediated intestinal reuptake of bile acids promotes hepatic expansion of regulatory T cells in murine sclerosing cholangitis
AASLD LiverLearning®, Ramesh Kudira, 195299
CCL4-induced cirrhosis and aging differentially modulate spingosine-1 phosphate receptors and sphingosine kinases in the brain
AASLD LiverLearning®, Yunzhou Li, 195300
The Apelin/Apelin receptor axis promotes biliary proliferation and liver fibrosis during biliary cholestasis
AASLD LiverLearning®, Marinda Scrushy, 195301
NTCP inhibition has hepatoprotective effects in cholestasis by lowering bile salt load on hepatocytes and increasing the biliary phospholipid vs bile salt ratio
AASLD LiverLearning®, Reinout Roscam Abbing, 195302
Cenicriviroc, a cytokine receptor antagonist, potentiated the effects of all-trans retinoic acid by reducing neutrophils and T cells in the liver of rodent cholestatic models
AASLD LiverLearning®, Dongke Yu, 195303
The thyromimetic GC-1 improves biliary injury but exacerbates hepatocyte injury in a mouse model of cholestasis
AASLD LiverLearning®, Kari Nejak-Bowen, 195304
Coffee mediated effects on transcriptional regulation of human UDP-glucuronosyltransferases (UGTs) during obstructive cholestasis (BDL) in a humanized transgenic UGT1A mouse model
AASLD LiverLearning®, Steffen Landerer, 195306